Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study
Clinical & Experimental Metastasis · 2025-02 · 42 (1)
DOI: 10.1007/s10585-024-10326-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical & Experimental Metastasis, online erschienen am 21.12.2024. Verfasst von Alexander Fabian und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str.3, 24105, Kiel, Germany. alexander.fabian@uks…. Hauptthemen laut MEDLINE: Breast Neoplasms, Radiosurgery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Schleswig-Holstein - Campus Kiel.
Abstract (Originalsprache)
Metastasis-directed therapy (MDT) for oligometastatic breast cancer (≤ 5 metastases) has shown little effect in specific scenarios of randomized trials. Therefore, we aimed to assess outcomes after metastasis-directed stereotactic radiotherapy (SRT) in various clinical scenarios. We conducted an international retrospective cohort study in thirteen centers including breast cancer patients receiving SRT to any metastatic site. Outcomes included local recurrence (LR), progression-free survival (PFS), and overall survival (OS). Cumulative incidence analysis was used for LR, Kaplan–Meier estimates for PFS and OS. Covariables included patient, disease, and SRT characteristics. We performed univariable and multivariable analyses (MVA). Among 444 patients, 751 metastases were treated with SRT. Of these, 73% were intracranial and 27% extracranial lesions. Oligometastatic disease (OMD) was present in 66% of the patients. LR after two years occurred significantly more often in intracranial (25%) versus extracranial lesions (7%). In MVA of patients with OMD treated for intracranial sites, higher performance status was significantly associated with longer PFS. Further, higher performance status, biologic subtype (HR-pos./HER2-pos.), and MDT to all sites were significantly associated with longer OS. In MVA of oligometastatic patients treated for extracranial sites, biologic subtype (HR-neg./HER2-pos.) and synchronous metastasis were associated with significantly longer PFS, whereas higher grading was associated with significantly shorter PFS. Moreover, biologic subtype (HR-neg./HER2-neg.) was associated with significantly shorter OS. In conclusion, the role of MDT for breast cancer may vary per clinical scenario. Patients with OMD treated for intracranial lesions who had MDT to all sites showed superior OS. Our results should be validated prospectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str.3, 24105, Kiel, Germany. alexander.fabian@uksh.de.
- Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
- Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
- Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Heidelberg Institute of Radiation Oncology (HIRO), 69120, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), 69120, Heidelberg, Germany.
Förderung
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
Zitieren
APA
Fabian, A., Buergy, D., Weykamp, F., Hörner-Rieber, J., Bernhardt, D., Boda-Heggemann, J., Pazos, M., Mehrhof, N., Kaul, D., Bicu, A. S., Badra, E. V., Rogers, S., Janssen, S., Hemmatazad, H., Hintelmann, K., Gkika, E., Lange, T., Ferentinos, K., Karle, H., …, & Krug, D. (2025). Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study. Clinical & Experimental Metastasis, 42(1). https://doi.org/10.1007/s10585-024-10326-x
Vancouver
Fabian A, Buergy D, Weykamp F, Hörner-Rieber J, Bernhardt D, Boda-Heggemann J, et al. Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study. Clinical & Experimental Metastasis. 2025;42(1). doi:10.1007/s10585-024-10326-x
BibTeX
@article{Fabian2025,
author = {Fabian, Alexander and Buergy, Daniel and Weykamp, Fabian and Hörner-Rieber, Juliane and Bernhardt, Denise and Boda-Heggemann, Judit and Pazos, Montserrat and Mehrhof, Nora and Kaul, David and Bicu, Alicia S and Badra, Eugenia Vlaskou and Rogers, Susanne and Janssen, Stefan and Hemmatazad, Hossein and Hintelmann, Katharina and Gkika, Eleni and Lange, Tim and Ferentinos, Konstantinos and Karle, Heiko and Brunner, Thomas and Wittig, Andrea and Nona-Duma, Marciana and Blanck, Oliver and Krug, David},
title = {Metastasis-directed stereotactic radiotherapy in patients with breast cancer: results of an international multicenter cohort study},
journal = {Clinical & Experimental Metastasis},
year = {2025},
volume = {42},
number = {1},
doi = {10.1007/s10585-024-10326-x}
}
EUVIMED